Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-11-28
2011-10-04
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S352000, C514S480000, C514S619000, C546S309000, C560S028000
Reexamination Certificate
active
08030518
ABSTRACT:
This invention is directed to compounds of formula I,where G is —O—, —S—, —C(g1)(g2)-, or —NH—, and n=1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is seizure disorders.
REFERENCES:
patent: 4181803 (1980-01-01), Morita et al.
patent: 4554281 (1985-11-01), vonBebenburg et al.
patent: 4668684 (1987-05-01), Tibes et al.
patent: 4778799 (1988-10-01), Tibes et al.
patent: 4923858 (1990-05-01), Engel et al.
patent: 4923974 (1990-05-01), Ueda et al.
patent: 5032591 (1991-07-01), Evans et al.
patent: 5162346 (1992-11-01), Lobisch et al.
patent: 5234947 (1993-08-01), Cherksey
patent: 5262419 (1993-11-01), Aberg et al.
patent: 5284861 (1994-02-01), Lobisch et al.
patent: 5384330 (1995-01-01), Dieter et al.
patent: 5428039 (1995-06-01), Cohen
patent: 5502058 (1996-03-01), Mayer et al.
patent: 5643921 (1997-07-01), Grover
patent: 5679706 (1997-10-01), D'Alonzo et al.
patent: 5760007 (1998-06-01), Shank
patent: 5800385 (1998-09-01), Demopulos et al.
patent: 5849789 (1998-12-01), Rostock et al.
patent: 5852053 (1998-12-01), Rostock et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5860950 (1999-01-01), Demopulos et al.
patent: 5914425 (1999-06-01), Meisel et al.
patent: 5925634 (1999-07-01), Olney
patent: 6117900 (2000-09-01), Rundfeldt et al.
patent: 6211171 (2001-04-01), Sawynok et al.
patent: 6218411 (2001-04-01), Koga
patent: 6265417 (2001-07-01), Carroll
patent: 6281211 (2001-08-01), Cai et al.
patent: 6326385 (2001-12-01), Wickenden et al.
patent: 6348486 (2002-02-01), Argentieri et al.
patent: 6395736 (2002-05-01), Parks et al.
patent: 6451857 (2002-09-01), Hurtt et al.
patent: 6469042 (2002-10-01), Hewawasam et al.
patent: 6472165 (2002-10-01), Rundfeldt et al.
patent: 6495550 (2002-12-01), McNaughton-Smith et al.
patent: 6500455 (2002-12-01), Frantsits
patent: 6537991 (2003-03-01), Shaw et al.
patent: 6538004 (2003-03-01), Drizin
patent: 6538151 (2003-03-01), Meisel et al.
patent: RE38115 (2003-05-01), Smith et al.
patent: 6589986 (2003-07-01), Bowlby et al.
patent: 6593335 (2003-07-01), Carroll
patent: 6642209 (2003-11-01), Fukunuga
patent: 6645521 (2003-11-01), Cassel
patent: 6737422 (2004-05-01), McNaughton-Smith et al.
patent: 7045551 (2006-05-01), Wu et al.
patent: 7160684 (2007-01-01), Argentieri et al.
patent: 7250511 (2007-07-01), Bavetsias
patent: 7309713 (2007-12-01), Rundfeldt et al.
patent: 7419981 (2008-09-01), Field et al.
patent: 2002/0013349 (2002-01-01), Wickenden
patent: 2002/0015730 (2002-02-01), Hoffmann et al.
patent: 2002/0183395 (2002-12-01), Argentieri
patent: 2004/0198724 (2004-10-01), McNaughton-Smith et al.
patent: 2005/0089473 (2005-04-01), Black et al.
patent: 2005/0089559 (2005-04-01), Szelenyi
patent: 2005/0090547 (2005-04-01), Szelenyi
patent: 2005/0202394 (2005-09-01), Dobson
patent: 2005/0277579 (2005-12-01), Krishnan et al.
patent: 2007/0066612 (2007-03-01), Khanzhin et al.
patent: 2542434 (2005-05-01), None
patent: 3337593 (1983-10-01), None
patent: 3604575 (1986-08-01), None
patent: 103 49 729.3 (2003-10-01), None
patent: 103 59 335 (2005-05-01), None
patent: 1 189 788 (1986-08-01), None
patent: 0 343 429 (1989-05-01), None
patent: 1 334 972 (2003-08-01), None
patent: 1 407 768 (2004-04-01), None
patent: 1 813 285 (2007-08-01), None
patent: 2000 14350 (2000-05-01), None
patent: 2000 143510 (2000-05-01), None
patent: 2006117525 (2005-12-01), None
patent: WO/00/55137 (2000-09-01), None
patent: WO 00/59487 (2000-10-01), None
patent: WO 00/59508 (2000-10-01), None
patent: WO 01/001970 (2001-01-01), None
patent: WO 01/01972 (2001-01-01), None
patent: WO 01/009612 (2001-02-01), None
patent: WO 01/22953 (2001-04-01), None
patent: WO 02/080898 (2002-10-01), None
patent: WO/03/020706 (2003-03-01), None
patent: WO/03/097586 (2003-11-01), None
patent: WO 03/106424 (2003-12-01), None
patent: WO 2004/082677 (2004-03-01), None
patent: WO 2004/058739 (2004-07-01), None
patent: WO 2004/080950 (2004-09-01), None
patent: WO 2004/096767 (2004-11-01), None
patent: WO 2004/096767 (2004-11-01), None
patent: WO 2004/105795 (2004-12-01), None
patent: WO 2005/087754 (2005-03-01), None
patent: WO 2005/039576 (2005-05-01), None
patent: WO 2005/048975 (2005-06-01), None
patent: WO 2005/100349 (2005-10-01), None
patent: WO 2006/029623 (2006-03-01), None
patent: WO 2006/092143 (2006-09-01), None
patent: WO 2008/024398 (2008-02-01), None
patent: WO 2008/066900 (2008-06-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Beeby et al. “The synthesis and properties of 2:7-Disubstituted 1:2:3:4-tetrahydroisoquinolines,”J. Chem. Soc.¶ 385, 1799-1803 (1949).
Reich et al., “Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysis,”J. Med. Chem.35:847-858 (1992).
Armand et al., “Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices,”Naunyn-Schmiedeberg's Arch Pharmacol359:33-39 (1999).
Armijo et al., “Ion channels and epilepsy,”Curr Pharm Des.11:1975-2003 (2005).
Barhanin, M., et al., “KvLQT1 and ISK (minK) proteins associate to form the IKScardiac potassium current,”Nature384(6604):78-80 (1996).
Bialer et al., “Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV),”Epilepsy Res.34:1-41 (1999).
Bialer, “Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI),”Epilepsy Res.51:31-71 (2002).
Bialer, “Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII),”Epilepsy Res.61:1-48 (2004).
Biervert et al., “A potassium channel mutation in neonatal human epilepsy,”Science279:403-406 (1998).
Blackburn-Munro and Jensen, “The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain,”Eur J Pharmacol.460: 109-116 (2003).
Brown and Adams, “Muscarinic suppression of a novel voltage-sensitive K+current in a vertebrate neurone,”Nature283:673-676 (1980).
Brown, D.A.,Ion Channels, T. Narahashi, Ed. (Plenum Press, New York) pp. 55-94 (1988).
Charlier et al., “A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family,”Nat Genet.18:53-55 (1998).
Cooper et al., “Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy.”Proc Natl Acad Sci USA97:4914-4919 (2000).
Delmas and Brown, “Pathways modulating neural KCNQ/M (Kv7) potassium channels,”Nat Rev Neurosci.6:850-862 (2005).
Dickenson al., “Neurobiology of neuropathic pain: mode of action of anticonvulsants,”Eur. J. Pain6:51-60 (2002).
Dost et al., “The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation,”Epilepsy Res.38:53-56 (2000).
Friedel and Fitton, “Flupirtine: a review of its analgesic properties, and therapeutic efficacy in pain states,”Drugs45:548-569 (1993).
Hiller et al., “Retigabine N-glucuronidation and its potential role in enterohepatic circulation,”Drug Metab Dispos.27(5):605-612 (1999).
Hunt and Mantyh, “The molecular dynamics of pain control,”Nat Rev Neurosci.2:83-91 (2001).
Jentsch, “Neuronal KCNQ potassium channels; physiology and role in disease,”Nat. Rev Neurosci., 1:21-30 (2000).
Jiang et al., “X-ray structure of a voltage-dependent K+ channel,”Nature423:33-41. (2003).
Kharkovets et al., “Mice with altered KCNQ4 K+channels implicate sensory outer hair cells in human progressive deafness,”EMBO J25:642-652 (2
Chen Huanming
Song Jianlan
Vernier Jean-Michel
Wu Jim Zhen
Jones Day
Kumar Shailendra
Valeant Pharmaceuticals International
LandOfFree
1,4 diamino bicyclic retigabine analogues as potassium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4 diamino bicyclic retigabine analogues as potassium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4 diamino bicyclic retigabine analogues as potassium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279266